Monte Rosa Therapeutics Inc. (GLUE)
GLUE trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1826457/000119312526109360/0001193125-26-109360-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | GLUE on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001826457 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $123.7M |
| Net income | -$38.6M |
| Operating income | -$54.2M |
| Net margin | -31.2% |
| Operating margin | -43.8% |
| Revenue growth | +63.5% |
| Cash | $129.9M |
| Total assets | $448.7M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 6.3× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $45.2M cash; operating cash flow -$41.4M a quarter. | Report 2026-09-30 |
| Shares outstanding | 85,450,119 (2026-10-30); 65,117,761 a year earlier; 50,081,023 three years earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-01-09 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-24 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $4.0M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $54.4M | $3.1M | -$41.0M | $45.2M | No debt tags | $70.3M | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $9.0M | -$43.4M | -$44.1M | $90.1M | No debt tags | $28.7M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $4.2M | -$44.5M | -$37.4M | $159.9M | No debt tags | $43.0M | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $2.8M | -$46.1M | -$43.0M | $129.9M | No debt tags | $123.7M | 10-K 2026-03-17 |
| Q3 2025 2025-09-30 | $12.8M | -$27.1M | $100.4M | $208.3M | No debt tags | $181.5M | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $23.2M | -$12.3M | -$34.7M | $69.4M | No debt tags | $178.0M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $84.9M | $46.9M | -$45.5M | $78.5M | No debt tags | $159.5M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $60.6M | $13.4M | $128.9M | $224.3M | No debt tags | $75.6M | 10-K 2026-03-17 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-02-11 |
| Latest annual report | 10-K | 2026-03-17 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEFA14A | 2026-04-29 |
Source: SEC EDGAR submissions feed, 405 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -11.4% |
| 1 month | -5.3% |
| 3 months | -40.8% |
| Year to date | -40.2% |
| 1 year | -34.6% |
| From 52-week high | -63.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| PRME | Prime Medicine Inc. | $4.19 | -1.87% | $762.3M |
| AURA | Aura Biosciences Inc. | $7.22 | +1.55% | $751.4M |
| SLDB | Solid Biosciences Inc. | $6.48 | -5.26% | $723.2M |
| MGTX | MeiraGTx Holdings plc | $8.74 | -4.79% | $854.2M |
| ATTO | Attovia Therapeutics Inc. | $14.72 | -2.68% | $673.1M |
| IMTX | Immatics N.V. | $6.17 | -3.44% | $923.2M |
| ODTX | Odyssey Therapeutics Inc. | $19.36 | +1.15% | $930.6M |
| DBVT | DBV Technologies S.A. | $10.27 | -6.76% | $645.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier